Clinical Trials | April 14, 2026
AbbVie Phase 2 data show 62% response rate in ovarian cancer combo trial
Highlights Mirvetuximab-based regimen promise
Highlights Mirvetuximab-based regimen promise
The centre offers a full spectrum of FDA-approved services, including physiotherapy, occupational therapy, speech and language therapy, and aqua therapy
The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care
Spread across nearly 4,500 sq. ft., the new clinic combines advanced dental technology, experienced specialists, and an Atithi-first care model
The license is valid for five years, effective from April 9, 2026
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
Green Vision Centres cut emissions, expand community coverage as partners align on resilient eye health systems
These surgeries involve no bone cuts, minimal surgical trauma, smaller incisions and significantly reduced blood loss
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups
Subscribe To Our Newsletter & Stay Updated
